Overview

An Open-Label, Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Androxal in Healthy Male Subjects After Oral Administration

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the route(s) of elimination and mass balance of enclomiphene after oral administration of a single 25 mg (approximately equivalent to [(~]) 500 nanocurie [nCi]) dose of [14C]Androxal in healthy adult male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

Repros Therapeutics Inc.

Collaborator:

Celerion

Treatments:

Clomiphene
Enclomiphene
Zuclomiphene